COMP <GO>
PCVX vs QGEN // FORWARD P/E MULTIPLE
Vaxcyte Inc. (NASDAQ) VS. Qiagen N.V. (NYSE) • 15-METRIC TALLY: PCVX 3
— QGEN 9
▲ FORWARD P/E MULTIPLE LEADER: QGEN
LAST: $62.03 (-0.93%) • MKT CAP: $9.85B
forward-pe
23.0x
LAST: $50.22 (-0.24%) • MKT CAP: $10.37B
forward-pe
22.7x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PCVX VS. QGEN)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | PCVX | QGEN | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 62.20% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -27.60% | 8.00% | -35.60 | QGEN | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 17.6x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -6.79% | 4.37% | -11.16 | QGEN | /fcf-yield <GO> |
| Operating Margin | -33.50% | 22.30% | -55.80 | QGEN | /operating-margins <GO> |
| Net Profit Margin | 0.00% | 20.30% | -20.30 | QGEN | /net-margins <GO> |
| Revenue Growth (YoY) | 19.80% | 5.70% | +14.10 | PCVX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.52% | -0.52 | QGEN | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 18.11 | 3.54 | +14.57 | PCVX | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 9/9 | -5.00 | QGEN | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 50.1 | 72.4 | -22.30 | QGEN | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.07 | 0.95 | +0.12 | PCVX | /macro-sensitivity <GO> |
| Forward P/E Multiple ACTIVE | 23.0x | 22.7x | +0.30 | QGEN | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $9.85B | $10.37B | -$519.6M | QGEN | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | PCVX REV | QGEN REV | PCVX GROSS % | QGEN GROSS % | PCVX FCF | QGEN FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $2.09B | — | 62.2% | -$669.3M | $453.3M |
| FY 2024 | $0 | $1.98B | — | 48.9% | -$475.1M | $506.4M |
| FY 2023 | $0 | $1.97B | — | — | -$296.8M | $371.0M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PCVX // BETA 1.07
QGEN // BETA 0.95